Enlivex Therapeutics Statistics
Total Valuation
ENLV has a market cap or net worth of $20.34 million. The enterprise value is -$2.62 million.
Important Dates
The next estimated earnings date is Friday, June 13, 2025, after market close.
| Earnings Date | Jun 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ENLV has 23.65 million shares outstanding. The number of shares has increased by 10.44% in one year.
| Current Share Class | 23.65M |
| Shares Outstanding | 23.65M |
| Shares Change (YoY) | +10.44% |
| Shares Change (QoQ) | +5.70% |
| Owned by Insiders (%) | 5.21% |
| Owned by Institutions (%) | 6.61% |
| Float | 17.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.02.
| Current Ratio | 6.84 |
| Quick Ratio | 6.56 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.95% and return on invested capital (ROIC) is -35.16%.
| Return on Equity (ROE) | -55.95% |
| Return on Assets (ROA) | -30.10% |
| Return on Invested Capital (ROIC) | -35.16% |
| Return on Capital Employed (ROCE) | -65.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$211,465 |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.69% in the last 52 weeks. The beta is 0.85, so ENLV's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -40.69% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 35.29 |
| Average Volume (20 Days) | 71,161 |
Short Selling Information
| Short Interest | 104,417 |
| Short Previous Month | 127,098 |
| Short % of Shares Out | 0.47% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -15.54M |
| Pretax Income | -25.99M |
| Net Income | -15.01M |
| EBITDA | -14.99M |
| EBIT | -15.54M |
| Earnings Per Share (EPS) | -$0.73 |
Full Income StatementBalance Sheet
The company has $23.50 million in cash and $534,000 in debt, giving a net cash position of $22.96 million or $0.97 per share.
| Cash & Cash Equivalents | 23.50M |
| Total Debt | 534,000 |
| Net Cash | 22.96M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 23.59M |
| Book Value Per Share | 1.00 |
| Working Capital | 22.19M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.01 million and capital expenditures -$103,000, giving a free cash flow of -$13.11 million.
| Operating Cash Flow | -13.01M |
| Capital Expenditures | -103,000 |
| Free Cash Flow | -13.11M |
| FCF Per Share | -$0.55 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |